Linked Life Data

21326202

Source:http://linkedlifedata.com/resource/pubmed/id/21326202

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7335
pubmed:dateCreated
2011-2-25
pubmed:abstractText
Inflammatory mechanisms influence tumorigenesis and metastatic progression even in cancers whose aetiology does not involve pre-existing inflammation or infection, such as breast and prostate cancers. For instance, prostate cancer metastasis is associated with the infiltration of lymphocytes into advanced tumours and the upregulation of two tumour-necrosis-factor family members: receptor activator of nuclear factor-?B (RANK) ligand (RANKL) and lymphotoxin. But the source of RANKL and its role in metastasis have not been established. RANKL and its receptor RANK control the proliferation of mammary lobuloalveolar cells during pregnancy through inhibitor of nuclear factor-?B (I?B) kinase-? (IKK-?), a protein kinase that is needed for the self-renewal of mammary cancer progenitors and for prostate cancer metastasis. We therefore examined whether RANKL, RANK and IKK-? are also involved in mammary/breast cancer metastasis. Indeed, RANK signalling in mammary carcinoma cells that overexpress the proto-oncogene Erbb2 (also known as Neu), which is frequently amplified in metastatic human breast cancers, was important for pulmonary metastasis. Metastatic spread of Erbb2-transformed carcinoma cells also required CD4(+)CD25(+) T cells, whose major pro-metastatic function was RANKL production. Most RANKL-producing T cells expressed forkhead box P3 (FOXP3), a transcription factor produced by regulatory T cells, and were located next to smooth muscle actin (SMA)(+) stromal cells in mouse and human breast cancers. The dependence of pulmonary metastasis on T cells was replaceable by exogenous RANKL, which also stimulated pulmonary metastasis of RANK(+) human breast cancer cells. These results are consistent with the adverse impact of tumour-infiltrating CD4(+) or FOXP3(+) T cells on human breast cancer prognosis and suggest that the targeting of RANKL-RANK can be used in conjunction with the therapeutic elimination of primary breast tumours to prevent recurrent metastatic disease.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1476-4687
pubmed:author
pubmed:issnType
Electronic
pubmed:day
24
pubmed:volume
470
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
548-53
pubmed:dateRevised
2011-9-5
pubmed:meshHeading
pubmed-meshheading:21326202-Animals, pubmed-meshheading:21326202-Antigens, CD4, pubmed-meshheading:21326202-Antigens, CD8, pubmed-meshheading:21326202-Breast Neoplasms, pubmed-meshheading:21326202-CD4-Positive T-Lymphocytes, pubmed-meshheading:21326202-Cell Line, Tumor, pubmed-meshheading:21326202-Female, pubmed-meshheading:21326202-Forkhead Transcription Factors, pubmed-meshheading:21326202-Genes, RAG-1, pubmed-meshheading:21326202-Humans, pubmed-meshheading:21326202-I-kappa B Kinase, pubmed-meshheading:21326202-Lung Neoplasms, pubmed-meshheading:21326202-Lymphocytes, Tumor-Infiltrating, pubmed-meshheading:21326202-Mice, pubmed-meshheading:21326202-Mice, Inbred C57BL, pubmed-meshheading:21326202-Neoplasm Metastasis, pubmed-meshheading:21326202-RANK Ligand, pubmed-meshheading:21326202-Receptor, erbB-2, pubmed-meshheading:21326202-Receptor Activator of Nuclear Factor-kappa B, pubmed-meshheading:21326202-Signal Transduction, pubmed-meshheading:21326202-T-Lymphocytes, Regulatory
pubmed:year
2011
pubmed:articleTitle
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling.
pubmed:affiliation
Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, California 92093, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural